Publications by authors named "M Ichijo"
Introduction The duration of diabetes mellitus (DM), blood pro-inflammatory markers, and dipeptidyl peptidase 4 (DPP4) activity are known predictors of diabetic kidney disease (DKD) progression in acute-onset type 1 DM (AT1DM) and type 2 DM. However, predictors of DKD progression in slowly progressive type 1 insulin-dependent DM (SPIDDM) have been less frequently studied. Patients and methods This retrospective cohort study included 60 patients with SPIDDM (definite) (26 men/34 women).
View Article and Find Full Text PDFContext: Moon-like facies (MLF) are a typical side effect of glucocorticoid (GC) therapy; however, its predisposing factors, relationship with GC-induced complications, and effects on body image are not well understood.
Objective: This study aimed to determine the predisposing factors for MLF during GC therapy; its association with GC-induced diabetes, hypertension, and dyslipidemia; and its effects on body image.
Methods: This prospective observational study spanned 24 weeks and targeted patients who received GC therapy at the University of Yamanashi Hospital from June 2020 to August 2022.
Article Synopsis
- RNF213 is linked to moyamoya disease and vasospastic angina, requiring a second hit like elevated thyroid peroxidase antibody (TPO-Ab) levels for the development of these conditions.
- A study analyzed 2,090 patients with ischemic stroke (IS) or transient ischemic attack (TIA), finding that 4.1% carried the RNF213 p. R4810K variant and had significantly higher TPO-Ab levels compared to non-carriers.
- The results suggest that elevated TPO-Ab levels are associated with the RNF213 p. R4810K variant, potentially influencing the likelihood of developing IS/TIA in these patients.
Prostasin (PRSS8) is a serine protease that metabolizes and moderates the effect of specific substrates. Epidermal growth factor receptor (EGFR), which modulates insulin secretion and pancreatic β-cell proliferation, is regulated via proteolytic shedding by PRSS8. We first detected PRSS8 expression in β-cells of pancreatic islets of mice.
View Article and Find Full Text PDFIntroduction: The aim of this study was to determine the safety and efficacy of intravenous (IV) alteplase at 0.6 mg/kg for patients with acute wake-up or unclear-onset strokes in clinical practice.
Methods: This multicenter observational study enrolled acute ischemic stroke patients with last-known-well time >4.